DMAC (DiaMedica Therapeutics) FCF Margin %: 0.00% (As of Mar. 2026)

What is DiaMedica Therapeutics FCF Margin %?

DiaMedica Therapeutics DMAC +1.75% 31 FCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates DMAC with a GF Score™ of 31/100. The stock has 1 warning sign investors should review. Among 959 Biotechnology companies, DiaMedica Therapeutics ranks worse than 104275.18% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. DiaMedica Therapeutics's Free Cash Flow for the three months ended in Mar. 2026 was $-9.09 Mil. DiaMedica Therapeutics's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, DiaMedica Therapeutics's FCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

As of today, DiaMedica Therapeutics's current FCF Yield % is -9.03%.

The historical rank and industry rank for DiaMedica Therapeutics's FCF Margin % or its related term are showing as below:

During the past 13 years, the highest FCF Margin % of DiaMedica Therapeutics was -1149.20%. The lowest was -1149.20%. And the median was -1149.20%.

DMAC's FCF Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -84.65
* Ranked among companies with meaningful FCF Margin % only.

DiaMedica Therapeutics FCF Margin % Related Terms

DiaMedica Therapeutics FCF Margin % Historical Data

* Premium members only.

The historical data trend for DiaMedica Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DiaMedica Therapeutics FCF Margin % Chart

DiaMedica Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

FCF Margin %

Get a 7-Day Free Trial

0.00

DiaMedica Therapeutics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
FCF Margin %	Get a 7-Day Free Trial															0.00	0.00	0.00	0.00	0.00

DMAC vs BCYC, RZLT, ABEO: FCF Margin % Comparison

For the Biotechnology subindustry, DiaMedica Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

DiaMedica Therapeutics FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, DiaMedica Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where DiaMedica Therapeutics's FCF Margin % falls into.

Save Embed

31GF Score

DiaMedica Therapeutics Inc DMAC

FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

DiaMedica Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

DiaMedica Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2025 )	/	Revenue (A: Dec. 2025 )
	=	-29.102	/	0
	=	%

DiaMedica Therapeutics's FCF Margin for the quarter that ended in Mar. 2026 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2026 )	/	Revenue (Q: Mar. 2026 )
	=	-9.09	/	0
	=	%

Frequently Asked Questions Learn more about FCF Margin % →

What does a FCF Margin % of 0.00% mean?

DiaMedica Therapeutics (DMAC) has a FCF Margin % of 0.00% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on DiaMedica Therapeutics and its competitors. According to the industry distribution chart, DiaMedica Therapeutics ranks #999999 out of 959 companies in the Biotechnology industry.

Is DiaMedica Therapeutics' FCF Margin % too high?

DiaMedica Therapeutics' current FCF Margin % is 0.00%. Based on the distribution chart, DiaMedica Therapeutics ranks #999999 out of 959 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, DiaMedica Therapeutics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.

How does DiaMedica Therapeutics' FCF Margin % compare to BCYC and RZLT?

According to the Biotechnology industry distribution chart, DiaMedica Therapeutics ranks #999999 out of 959 companies for FCF Margin %. This places DiaMedica Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good FCF Margin % for a Biotechnology company?

A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high FCF Margin % mean?

A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on DiaMedica Therapeutics and its competitors. DiaMedica Therapeutics's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is DiaMedica Therapeutics stock overvalued right now?

DiaMedica Therapeutics (DMAC) has a current FCF Margin % of 0.00%. The current FCF Margin % is 0.00%. DiaMedica Therapeutics' overall GF Score™ is 31/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is FCF Margin % calculated?

FCF Margin % is calculated from a company's financial statements. For DiaMedica Therapeutics (DMAC), the current FCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

DiaMedica Therapeutics Business Description

Industry Healthcare Biotechnology

Comparable Companies BCYC RZLT ABEO FATE LCTX TENX RCKT IVVD PRLD NAGE VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Address 301 Carlson Parkway, Suite 210, Minneapolis, MN, USA, 55305

Website https://www.diamedica.com

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.

31GF Score

Get the complete analysis for DMAC

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.36

Price

View DMAC Analysis

See FCF Margin % data for all stocks →